I spent the last two weeks at two exciting neurotech conferences. At NYBCI, the community came together to discuss a corner of neurotechnology that is receiving unprecedented attention. Afterwards, I travelled to San Francisco for the Neurotech Leaders Forum, a conference bringing together leaders from across the wider field.
Inspired by these conferences, we're updating our biweekly newsletter to better track what's happening across the neurotech ecosystem. Market Notes will now highlight the most important trends from the past two weeks, spotlight a startup making moves, and round up the remaining developments from the fortnight.

Blackrock Neurotech’s Utah Array was used in an auditory nerve implant that passed bench testing, with nearly all electrodes surviving 1.5 years of simulated aging and 6.3 billion stimulation pulses. The team calls it a step toward first-in-human trials.

Precision Neuroscience opened its first clinical site outside the US at Cleveland Clinic Abu Dhabi. The expansion will allow Precision to test its Layer 7 implant and procedures inside a new health system, as Abu Dhabi continues attracting life sciences research.

Neuralink reported first data from its VOICE speech trial. One participant with ALS reached 75 words per minute at a 5.8% word error rate in their first week, on a 125,000-word vocabulary. The early feasibility study will include six participants.

Cognixion is building a non-invasive BCI that pairs EEG with eye tracking and AI-suggested phrases. Eye tracking points to an option, the visual cortex signal confirms it. Its new NIH-funded CHOICE study will check if users prefer the system over traditional eye trackers. In a previous home study, run on Apple Vision Pro, median speed across four participants was 8.6 words per minute. One participant with late-stage ALS reached 12.3, against 4.5 on their existing eye tracker. That is much lower than implanted BCI or average spoken speech, but any improvement can provide giant value for this population.

At the end of October, Shanghai-based NeuroXess announced a $98 million Series B to advance its fully implanted, wireless BCI. The company is quickly progressing towards regulatory approval in China.

electroCore submitted a 510(k) application seeking clearance for its Quell wearable in chronic chemotherapy-induced peripheral neuropathy. In a 142-person sham-controlled trial, pain scores fell about 40% with active treatment versus 24-33% with sham.

Wave Neuroscience and Ampa will bring Wave’s EEG-guided MeRT protocols to the portable Ampa One TMS system. Clinics that license MeRT can now run it on Ampa units they already have.
.jpeg)
Wave Neuroscience and Ampa will bring Wave’s EEG-guided MeRT protocols to the portable Ampa One TMS system. Clinics that license MeRT can now run it on Ampa units they already have.

Samphire Neuroscience’s Nettle headband gained an expanded UK and EU intended purpose covering mood symptoms of PMDD. In a 42-person sham-controlled, nonrandomized study, GAD-7 anxiety scores fell 6.4 points versus 2.1 with sham.

BrainsWay launched a collaboration with Mindful Health Solutions covering access to Deep TMS, Neurolief’s at-home Proliv Rx, and physician education. No financial terms or system numbers were disclosed.

StimCardio closed an oversubscribed $30M Series A for Rhyvive, a wrist-worn nerve stimulator used alongside catheter ablation for atrial fibrillation. The round funds the NeuroPulse 2 pivotal study and preparation of an FDA De Novo submission. Neuromodulation is expanding across the body.

UK-based Neurovalens already markets Modius Lean, a wearable that stimulates the vestibular system through electrodes behind the ears. Last year, it received FDA authorization to support weight management. A clinical trial involving 241 participants found significant reductions in visceral fat, although the study missed its primary weight-loss endpoints.

Empatica launched WellPD, an FDA-cleared and CE-marked home-use wrist wearable that tracks tremor, dyskinesia, bradykinesia, sleep, and activity for people with Parkinson’s. WellPD is available in the US, Canada, the UK, Australia and 14 European countries.

Another interesting one is US-based SynchNeuro, which is working on an EEG wearable that infers glucose levels from brain activity.

Last week, China’s BrainCo stated that ambition on the record, announcing plans for a brain stimulation wearable that suppresses appetite. The company calls it an electronic GLP-1 and hopes to launch it in China within two to three years. How exactly the tech works remains unclear.

Synaptive Medical was acquired by Globus Medical. Globus is adding Synaptive’s surgical visualization, navigation, and planning tools to its cranial neurosurgery portfolio. Terms were not disclosed.

The approaches are wonderfully diverse. NeuroBionics, led by Nicolette Driscoll, is developing endovascular technology for deep brain stimulation. Researchers at Imperial College London are exploring miniature acoustic sensors that record activity from inside blood vessels.